http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results
-
Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer
-
Xilio Therapeutics (XLO) Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
-
Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors
-
Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results
-
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
-
Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results
-
Xilio Therapeutics to Present at Upcoming Investor Conferences
-
Xilio Therapeutics to Present at Upcoming Investor Conferences
-
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
-
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit
-
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
-
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day
-
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12
-
Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12
-
Xilio Therapeutics (XLO) Announces Pipeline and Business Updates, Reports Q3
-
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
-
Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results
-
Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit
-
Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next’ Summit
-
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
-
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference
-
Xilio Therapeutics (XLO) Appoints Tomas J. Heyman to its Board
-
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors
-
Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors
-
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
-
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
-
Xilio Therapeutics (XLO) Reports Positive Prelim Phase 1 Dose-Escalation Data for XTX101
-
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial
-
Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial
-
Xilio Therapeutics (XLO) Announces Promotion of Martin Huber, M.D., to President
-
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
-
Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President
-
Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference
-
Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference
-
Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer
-
Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer
-
Xilio Therapeutics (XLO) Reports Pipeline and Business Highlights
-
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results
-
Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results
